If you are patient, Cipla is a good buy: Devang Visaria
Devang Visaria, chief strategist, Devangvisraia, in a chat with ET Now talks about the pharma stocks.
Aurobindo Pharma has been one of the best performing pharma stocks over the last few months but currently right now, it is hovering around its 52-week high. If it sustains about those levels, then it could again continue to outperform the markets.
On the other hand, we would like Cipla from an investment perspective from this level - around 310 to 290 is a very strong support for the stock and if one is a patient investor and having a horizon of around 3-6 months, then you could consider buying a Cipla in staggered quantities.
Download ET Markets APP